Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers

NCT04630574 | Completed

• 1 other identifier: CHUBX 2018/67
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 2

Brief Summary

The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.

Conditions

Huntington Disease

Keywords

Huntington's disease; Dysarthria; Motor speech performance; Acoustic markers

Outcome Measures

Primary Outcomes (8)

• Determination of the intelligibility score.

  Defined as the number of words correctly recognized by the evaluator (score out of 15).

  Day 1

• Determination of the maximum phonation time.

  Expressed in milliseconds.

  Day 1

• Determination of the phonation characteristics.

  Described as the mean and standard deviation of fundamental frequency (in Hz),

  Day 1

• Determination of the intensity modulation capacities.

  Based on a scale of 0 to 4.

  Day 1

• Determination of the Coarticulation.

  Expressed in Hz. Extracted from the spectral properties of the acoustic signal of certain words.

  Day 1

• Determination of the prosody.

  assessed on a scale 0 to 4 on particular sentences.

  Day 1

• Determination of the diadocokinesies,

  assessed on two scales: precision (0 to 4) and control (0 to 4).

  Day 1

• Determination of the articulation rate.

  expressed in syllabs per second.

  Day 1

Secondary Outcomes (3)

• Determination of the Huntington's disease stage.

  Day 1

• Determination of the clinical motor forms of the Huntington's disease.

  Day 1

• Determination of the level of cognitive impairment

  Day 1

Study Arms (1)

Patients with Huntington's disease

Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.

Other: Speech evaluation with the clinical evaluation of dysarthria; Other: complete assessment of the MonPaGe computerized protocol

Interventions

Speech evaluation with the clinical evaluation of dysarthria OTHER

A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.

Patients with Huntington's disease

complete assessment of the MonPaGe computerized protocol OTHER

The application records directly and anonymously stores speech productions made by the patient.

Patients with Huntington's disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with Huntington's disease at presymptomatic and declared stages of the disease.

You may qualify if:

• major patients
• francophone patients
• Huntington's disease carriers confirmed by molecular biological analysis
• carriers of pre-symptomatic Huntington's disease: Total Motor Score of the Unified Huntington's Disease Rating Scale \<5
• carriers of Huntington's disease at a declared stage: Total Motor Score of the Unified Huntington's Disease Rating Scale ≥ 5
• followed in the Competence Center Huntington's disease Bordeaux Hospital or in the Reference Center Huntington's disease Henri Mondor Hospital of Créteil
• affiliates or beneficiaries of a social security scheme
• Finally, a free, informed and express consent of the patient must be collected.

You may not qualify if:

• Huntington's disease patients with severe dysarthria (BECD score\> 16), acoustic analysis not being possible on unintelligible speech
• patients placed under the protection of justice

Sponsors & Collaborators

• University Hospital, Bordeaux: lead
• Centre National de la Recherche Scientifique, France: collaborator

Study Sites (2)

Hôpital Henri-Mondor

Créteil, France

Location

Centre Hospitalier Universitaire de Bordeaux

Talence, France

Location

MeSH Terms

Conditions

Huntington Disease; Dysarthria

Condition Hierarchy (Ancestors)

Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Dementia; Chorea; Dyskinesias; Movement Disorders; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Articulation Disorders; Speech Disorders; Language Disorders; Communication Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2020
• First Posted: November 16, 2020
• Study Start: February 23, 2021
• Primary Completion: February 5, 2024
• Study Completion: February 5, 2024
• Last Updated: February 20, 2024

Record last verified: 2024-02

Locations

FR (2)